ImportRefusal LogoImportRefusal

Novo Nordisk Pharmaceutical

⚠️ High Risk

FEI: 3007569767 • Sao Paulo, Sao Paulo • BRAZIL

FEI

FEI Number

3007569767

📍

Location

Sao Paulo, Sao Paulo

🇧🇷

Country

BRAZIL
🏢

Address

Avenida Francisco Matarazzo 1500, , Sao Paulo, Sao Paulo, Brazil

High Risk

FDA Import Risk Assessment

60.2
LowModerateHighCritical

This firm has a significant history of FDA import refusals with notable violations.

Statistics

6
Total Refusals
3
Unique Violations
12/11/2025
Latest Refusal
10/6/2014
Earliest Refusal

Score Breakdown

Violation Severity
76.7×40%
Refusal Volume
31.3×30%
Recency
98.2×20%
Frequency
5.4×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

756×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

1182×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

32801×

FRNMFGREG

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.

Refusal History

DateProductViolationsDivision
12/11/2025
61PAA72SEMAGLUTIDE (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/29/2025
61PDY72SEMAGLUTIDE (ANTI-DIABETIC)
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
8/22/2025
61PBY72SEMAGLUTIDE (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/17/2024
61PCP72SEMAGLUTIDE (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
11/30/2023
66VDY99MISCELLANEOUS PATENT MEDICINES, ETC.
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/6/2014
66VDK99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
New Orleans District Office (NOL-DO)

Frequently Asked Questions

What is Novo Nordisk Pharmaceutical's FDA import refusal history?

Novo Nordisk Pharmaceutical (FEI: 3007569767) has 6 FDA import refusal record(s) in our database, spanning from 10/6/2014 to 12/11/2025.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Novo Nordisk Pharmaceutical's FEI number is 3007569767.

What types of violations has Novo Nordisk Pharmaceutical received?

Novo Nordisk Pharmaceutical has been cited for 3 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Novo Nordisk Pharmaceutical come from?

All FDA import refusal data for Novo Nordisk Pharmaceutical is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.